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Extended Abstract
Introduction: Cancer has a difficult therapeutic process. Treat-
ment procedures of cancer cause the child be often tired and languish-
ing. These children are also more prone to infections and frequently
are hospitalized that leads to the separation of children from their
families and the community. Pain, fatigue, anxiety, and other symp-
toms are common in those experiencing cancer.
Satin, Linden and Philips (2009), in ameta-analysis study found that
the risk of death in cancer patients that report depressive symptoms is
more than non-depressed patients, The rate of death in patients who
show some symptoms of depression is 25%, and in patients with mild
or major depression is 39% more than other cancer patients.
Since childhood cancer is a life-threatening disease, the role of
parents, especially mothers as a primary carer, are increasingly high-
lighted and because of changes in the role of parents, parents are fac-
ing with multiple and complex problems.
Parents often have feelings of depression and anxiety. Patient and
caregiver characteristics, stressors, stress appraisal, stress coping
methods, and social support influence caregivers' quality of life. Stud-
ies show that mothers of children with cancer report more perceived
stress than mothers of healthy children and even mothers of children
with Down syndrome. Studies also show that parents of children sur-
vivors of cancer show significantly higher levels of post-traumatic
stress symptoms compared with healthy children parents.
Play therapy allows children to encounter with emotional needs
and doubts, and provide an opportunity to find ways to cope with their
hospital circumstances. On the other hand children need sufficient
time to engage emotionally with their parents, and parents should
know that how interact with their children in an efficient way. The
way in which mothers interact with their children is very important.
Since play therapy is one of the best ways to get into the child's world
and it can also have a positive impact on the children's physical and
mental health, so if the mothers enter this field, the play can be an
effective way for mothers to interact with their children.
Material and methods: Participants: Participants were recruited
from the inpatient oncology unit at Dr. Sheikh Hospital in the city of
Mashhad, Iran, over a 5 month period. Patients were included in the
study if their diagnosis was cancer, they were between 7-12 years old,
their mothers were primary caregiver and were capable of participat-
ing in a 1-hour 8 sessions of play therapy. So 14 children diagnosed
with cancer and their mothers (28 individuals) entered in final
program.
Measures and procedure: The instruments used to measure
depression symptoms, perceived stress and Parent-Child Relationship
were Perceived Stress Scale (PSS), Child depression inventory (CDI),
and Parent-Child Relationship Scale (PCRS).
Perceived stress scale: This scale has three versions with 4, 10
and 14 items respectively. Cohen et al (1983), conducted a study to
evaluate the psychometric properties of all these three versions. Cron-
bach's alpha of 14-item version was 0/84 and 0/86. In a study carried
out by Ghorbani et al (2002) in the Iranian society, Cronbach's alpha
was 0/81.Child depression inventory: It is a self-assessment scale devel-
oped by Kovacs (1977), which was designed to assess signs of cogni-
tive, behavioral and emotional depression in children and adolescents
aged 7 to 17. In Dehshiri, Najafi, sheikhi and Habibi Askarabad
(2009) test-retest reliability and internal consistency of the question-
naire respectively was 0/82, 0/83
Parent-child relationship scale: This scale was developed by
Pianta for the first time in 1994. It contains 33 items that assesses
parental perception of their relationship with their child. It is applied
for children aged 3-12. This questionnaire was translated by Tahma-
sian in 2007 and its validity was assessed by experts.
First the participants answered the PSS, PCRS and CDI question-
naires as pre-test. Then the individuals in intervention group received
8 sessions of parent e child play therapy, at the end, both of interven-
tion and control group filled post-test questionnaires.
Result: Whit regard to depression, the analysis of covariance data
showed a significant change between pre-test and post-test
(F(1,11)¼92/34, p < 0/001, ¼,0/89). In other words, there is a signif-
icant difference in depression scores between the subjects of experi-
mental and control groups at post-test. Post-test scores of Depression
in the experimental group were significantly lower than the control
one.
In the case of perceived stress variable, after controlling the effect
of pre-test scores, the efficacy of treatment in post-test scores was not
significant (F(1,11)¼1/40,p < 0/05, ¼,0/11). So, there is no a signifi-
cant difference between the subjects of experimental and control
groups in mean scores for perceived stress of mothers in the post-test.
For child-parent relationship, there is a significant relationship
between pre-test and post-test scores of this variable. The results in
the table above shows After controlling effect of pre-test scores, the
efficacy of treatment for child-parent relationship in post-test scores
are also significant(F(1,11)¼12/84,p < 0/01, ¼,0/53). So, there is a
significant difference between the mean scores of parent-child rela-
tionship in the post-test in subjects of the experimental and control
groups.
Discussion and conclusion: Childhood cancer is one of the most
painful diseases for children and families. This illness can threaten
the mental health of the child and his family. Children encounter
with painful side effects of cancer medical treatments, such as nausea,
vomiting, hair loss, fatigue, pain and etc. And because of diseases
children cannot participate in peers and family communities, their
life change considerably. Children with cancer are more likely to
experience symptoms of depression and, compared with other chil-
dren, and the risk of death in the children that represent more symp-
toms of depression is more than other children.
Also psychological conditions of the children’s’ parents affect the
child behaviors and emotions. Children who have a better relationship
with their parents and their parents experience less stress, have less
behavioral problems and greater adherence to treatment.
Psychological interventions that aim these problems are great help
for these children and their parents. One of these interventions is play
therapy that is enjoyable activity for children. On the other side,
involvement of parents in treatment can lead to better results.
Current study also aims to reduce the symptoms of childhood
depression, reduce perceived stress on their mothers and improve
parent - child relationship used parent child play therapy. Parent-child
play therapy involves child and his parent in enjoyable and purposeful
activities, to express emotions and thoughts in a secure atmosphere.
Training of relaxation techniques to both child and mother and to
instruct empathy and behavior management techniques to mother
helps to solve parent and child psychological problems. Intervention
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depression and improve parent e child relationship, but it is not
effective on reducing of mothers Perceived stress.
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Extended Abstract
Introduction: The first description of p53 protein is in 1979 and
since that time there have been more than 35 000 papers published on
this topic. However even after 30 years after its discovery, it is still
somewhat of a mystery. The gene encodes transcription factor p53
is TP53, one of the most commonly altered genes in human cancers.
P53 protein plays a central role to regulate cell cycle progression, dif-
ferentiation, senescence, DNA repair, and apoptosis. In response of
DNA damage or other stress signals, p53 activity is up-regulated
and a series of biological events cascade is initiated that eventually
results in prevention of tumor development and expansion. Recent
studies showed, about 50% of human cancers have p53 mutation
but the frequency varies considerably between cancer types, ranging
from ~10% in hematopoietic malignancies to 50e70% in ovarian,
colorectal and head and neck cancers. Mutations in p53 dissolve its
normal tumor suppressor functions finally contributing to the survival
and/or amplification of aberrant cells with poorly differentiated phe-
notypes. Cancer cells with mutant p53 are associated more aggressive
disease, increased resistance to radiation therapy and chemotherapy,
with poor prognosis of the disease.
Dominant negative mutation of TP53 gene: The presence of
p53 mutation in cell does not necessarily mean it loses p53 activity,
when a cell has a wild type allele together with the mutant one. In
this heterozygous state it should be known that, this cell may con-
tain a trans dominant mutation with reduced p53 activity and then
confer a growth advantage and other tumorogenesis signs. Moreover,
p53 mutant cancer cells which contain a dominant-negative activity
or Gain Of Function (GOF) activity that inactives hetero-oligomers
of the mutants with the wild-type protein. Dominant-negative p53
mutation results in the total abrogation of p53 protein function,
even if cells still have wild-type protein expression. Increasing evi-
dence showed that many p53 mutant cells also gain new oncogenic
properties that are independent from wild-type one. p53 mutants that
promote tumor progression or/and resistance to therapies become
the most common prognostic marker for both tumor recurrence
and death caused by cancer. These mutation reduce the ability of
the wild type p53 to bind to its target gene responsive element.
For example, in one study, mutant TP53 was found in 24 of 92
(26.1%) endometrial cancers, in which 14 cases showed dominant-
negative activity that was associated with progressed stages, non
endometrioid type tumors. It showed, the presence of a dominant
negative mutant p53 was related to poor outcomes, suggesting that
dominant negative mutant TP53 should play a pivotal role in the
progression of endometrial cancer.
TP53 cancer gene therapeutic way: On the result of many
researches that p53 inactivation is common in human cancers, it
may be assumed that reactivation of p53 and functional restoration
of the p53 tumor suppressor pathway is a potential and detrimental
therapeutic way against cancer. Gene therapy using wild-type p53,delivered by adenovirus vectors, is now widespread and other bio-
logic approaches like the development of oncolytic viruses designed
to replicate and kill only p53 defective cells. The other way is the
development of siRNA and antisense RNA's that activate p53 by
inhibiting the function of the negative regulators Mdm2, MdmX,
and HPV E6 is effective too. In conclusion Adenovirus-based p53
gene therapy as well as using small molecules include PRIMA that
can restore the transcriptional function to mutant p53 cell, or NUT-
LIN and RITAwhich interfere with MDM2-directed p53 degradation,
have been tested in a preclinical stage and some of these approaches
are currently in clinical development.
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Introduction: Breast cancer is the most common cause of malig-
nancy and cancer mortality among women in the less developed
(LDCs) and more developed (MDCs) countries worldwide. Global sta-
tistics indicate the annual incidence of breast cancer is increasing and
this is happening faster in countries with a low incidence rate of breast
cancer. Both environmental and genetic factors are involved in the risk
of breast cancer. Genetic risk factors such as variations in TOX3 which
contribute to the liability play an important role in the development of
the disease. In regard to the latter, genome wide association studies
(GWAs) has identified low penetration but high frequency disease-
associated single nucleotide polymorphisms (SNP) in a number of
genes, such as the HMG-box nuclear protein TOX high mobility group
box family member 3 (TOX3). TOX3, also known as TNRC9, is a
non-histone chromatin protein including anuclearlocalization signal
(NLS) and a high mobility group (HMG)-box domain followed by a
C-terminal polyglutamine stretch. The HMG-box super family is
described by a ~80 amino acid DNA-binding domain, and individual
members function such as regulation of gene expression, chromatin
remodeling, DNA repair, and genomic stability.
Previous data indicated that TOX is a sequence-independent
HMG-box DNA-binding protein.TOX3 maps to chromosome 16q12
and consists of seven exons. TOX3 is a region regularly lost in breast
cancers and is involved in the risk of spreading breast cancer. How-
ever, there is little data on TOX3 and breast cancer although TOX3
has profound effects on regulation of cellular activity during initia-
tion, maintenance, or developing of cancer.
TOX3 is highly expressed in the central nervous system (CNS), in
the ileum, and within the brain in the frontal and occipital lobe in nor-
mal human tissues as well as in breast tumor at a higher level than in
normal tissue. TOX3 risk-allele carriers have been reported to develop
more lobular breast tumors, and patients with this SNP who develop
luminal A (LumA) breast tumors have shorter overall survival.
TOX3 has calcium-dependent transcriptional activity and is a co-fac-
tor of cAMP response element (CRE)-binding protein (CREB) and
CREB-binding protein (CBP). RNAi-mediated knockdown of the
endogenous TOX3 resulted in significant reduction of calcium-
induced c-fos expression and complete inhibition of calcium
